Key Drivers
- Margin Strength
- High Leverage
- Weak Cash Flow
AIAI Summary
IRTC remains an attractive growth business with strong demand and ~71% gross margins, but the investment case now hinges on management proving trust, legal containment, and consistent free-cash-flow conversion because litigation and uneven cash generation are likely to cap the valuation until execution is clearly de-risked.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •High Leverage
- •Weak Cash Flow
IRTC combines strong gross margins and solid liquidity with positive annual cash flow, but persistent operating losses, heavy leverage, and negative free cash flow in the latest quarter keep the outlook risky.
Price Behavior
Key Price Behavior Insights:
- •Trend Reversal
- •Reclaimed Support
- •Overbought Stretch
IRTC has turned sharply bullish with a sequence of higher highs and higher lows, reclaimed $118–$119 as support, and is now testing resistance near $126.48 with some short-term overbought risk.
Sharp drop from $113.76 to $101.79 on 2026-06-17, followed by a rapid rebound
Sentiment & News
Key News Insights:
- •Disclosure scrutiny
- •Shareholder lawsuits
- •Contained cyber incident
iRhythm faces intensifying shareholder litigation over alleged disclosure failures tied to the Zio AT monitor, while its reported cyber incident appears contained with no stated impact on patient safety or core operations.
The stock may face near-term headline pressure from legal uncertainty, but the limited cyber impact suggests the operational risk remains manageable
Similar Companies in Healthcare
Other companies in the same sector with AI ratings